

2-Aminobenzothiazole As A Privileged Scaffold in Drug Discovery: Recent Advances and Challenges

Mahesh, Dept. of Pharmaceutical Chemistry, Research Scholar, SunRise University, Alwar(Rajasthan)
Dr. Tekade Bharat Wasudeo, Professor (Dept. of Pharmaceutical Chemistry), SunRise University, Alwar (Rajasthan)

ABSTRACT

2-Aminobenzothiazole is a versatile heterocyclic scaffold that has garnered significant attention in the field of drug discovery due to its diverse biological activities and potential therapeutic applications. This review paper aims to provide a comprehensive overview of the recent advances and challenges associated with utilizing 2-aminobenzothiazole as a privileged scaffold in drug discovery. We discuss the synthesis methods, structural modifications, and the diverse range of biological targets where this scaffold has shown promising activity. Additionally, the paper addresses challenges related to its pharmacokinetic properties, toxicity profiles, and intellectual property issues. Overall, the research highlights the potential of 2-aminobenzothiazole as a valuable scaffold for developing novel therapeutic agents, while acknowledging the hurdles that need to be addressed for successful translation into clinical applications.

Keywords: 2-Aminobenzothiazole, Heterocyclic Scaffold, Drug discovery

INTRODUCTION

The benzothiazole core is a fundamental chemical structure that appears in many biologically active molecules. This core consists of a fused ring system composed of a benzene ring and a thiazole ring, resulting in a unique arrangement that contributes to the compound's functional properties. The benzothiazole core has gained significant attention in pharmaceutical research due to its remarkable capacity to interact with various biological targets, making it a valuable structural motif for the development of new drugs. This paper focuses specifically on one of its derivatives, namely 2-aminobenzothiazole, which holds a prominent place in drug discovery due to its versatile biological activities and ease of synthesis.

Structural Characteristics of Benzothiazole Core:

The benzothiazole core is comprised of a six-membered benzene ring fused with a five-membered thiazole ring. This arrangement provides several features that are beneficial for drug development:

Aromatic System: The benzene ring contributes to the compound's aromatic nature, which is often associated with biological activity. Aromatic systems can engage in various interactions with proteins, nucleic acids, and other biological macromolecules, influencing the compound's binding affinity and activity.

Heterocyclic Moiety: The thiazole ring, being a heterocycle (a ring containing atoms of different elements), imparts distinct electronic and steric properties to the compound. This can influence how the compound interacts with target proteins and enzymes.

Functional Groups: The benzothiazole core can be functionalized with various substituents at different positions, further diversifying its properties and interactions with biological molecules.

2-Aminobenzothiazole:

Among the derivatives of the benzothiazole core, 2-aminobenzothiazole stands out due to its unique combination of structural features and biological activities. This derivative contains an amino group (-NH₂) at the 2-position of the thiazole ring. This amino group not only enhances the compound's solubility and reactivity but also introduces a potential site for additional modifications.

SYNTHESIS METHODS AND STRUCTURAL MODIFICATIONS

Synthesis Methods for 2-Aminobenzothiazole: The synthesis of 2-aminobenzothiazole typically involves cyclization of suitable precursors, leading to the formation of the benzothiazole core with an amino group at the 2-position of the thiazole ring. Different strategies have been employed to achieve this cyclization:

Ring Closure Reactions: One common approach involves the cyclization of precursors containing an amine group and a thiol group. The amine reacts with the thiol under appropriate conditions to form the benzothiazole ring system.

Step 1: Start with a precursor molecule containing an amine group (NH_2) and a thiol group (SH) in appropriate positions. Let's represent the precursor as R-NH_2 and R-SH , where R represents the rest of the molecule.

Step 2: The first reaction is the formation of a thiazoline intermediate. The thiol group (R-SH) reacts with the amine group (R-NH_2) to form a cyclic thiazoline compound, with the amine nitrogen and the sulfur atom of the thiol group coming together to close the ring. This reaction is a nucleophilic substitution reaction involving the amine and thiol groups.

Reaction 1: Thiazoline Formation



Step 3: In the next step, the thiazoline intermediate undergoes an intramolecular cyclization reaction. The sulfur atom in the thiazoline attacks the adjacent carbon in the molecule, leading to the formation of the benzothiazole ring system.

Reaction 2: Benzothiazole Ring Formation



The final product is the desired benzothiazole core with an amino group at the 2-position of the thiazole ring. The reaction sequence involves the initial formation of a thiazoline intermediate followed by the intramolecular cyclization to form the benzothiazole ring.

Condensation Reactions: Another strategy includes the condensation of o-aminothiophenols with appropriate carbonyl compounds, such as aldehydes or ketones, resulting in the formation of the benzothiazole ring.

Step 1: Begin with an o-aminothiophenol, which has an amino group (NH_2) and a thiol group (SH) on adjacent carbon atoms in the phenyl ring.

Step 2: Introduce an appropriate carbonyl compound, such as an aldehyde or a ketone. Let's use an aldehyde (RCHO) as an example.

Step 3: The amine group of the o-aminothiophenol acts as a nucleophile and attacks the carbonyl carbon of the aldehyde. This forms a new carbon-nitrogen bond and leads to the formation of an imine intermediate.

Reaction 1: Imine Formation



Step 4: The imine intermediate undergoes intramolecular cyclization. The sulfur atom in the thiol group attacks the carbon in the imine linkage, forming a new carbon-sulfur bond. This process results in the closure of the benzothiazole ring and the release of a water molecule.

Reaction 2: Benzothiazole Ring Formation



The final product is the desired benzothiazole core with an amino group at the 2-position of the thiazole ring.

Advancements in Synthesis: Recent years have seen significant advancements in synthetic methodologies for accessing 2-aminobenzothiazole and its derivatives:

Transition Metal-Catalyzed Reactions: Transition metal-catalyzed processes, such as C-H functionalization, have enabled efficient and selective synthesis of 2-aminobenzothiazole derivatives. These methods can lead to the direct formation of the benzothiazole core from readily available starting materials.

Step 1: C-H Activation- The C-H activation step involves the coordination of a palladium catalyst to the C-H bond of the starting material. This activates the C-H bond and makes it susceptible to further reactions. A directing group is often used to guide the palladium catalyst to the desired C-H bond. Here's an illustrative example of the C-H activation step:

Starting Material: N-Methylbenzothiazole (with a directing group R at the 6-position)


Catalyst: Palladium (Pd) with ligands (L)



Step 2: Amination - In this step, an amine source is introduced to facilitate the transfer of the amino group to the activated C-H position. This leads to the formation of a C-N bond. The amine source could be an amine reagent or an amine precursor.



Step 3: Thiazole Ring Formation- While the amination step is occurring, the thiazole ring is simultaneously formed. This can be achieved by the condensation of a thiol (containing sulfur) with an electrophilic reagent (often a halide or sulfonyl chloride).



Step 4: Final Product- Combining the C-N and C-S bond formations results in the formation of 2-aminobenzothiazole derivatives. The palladium catalyst is regenerated during the reaction and can be used in subsequent cycles.

Microwave-Assisted Techniques:

The general synthesis of 2-aminobenzothiazoles involves the reaction between o-aminothiophenol and an appropriate carbonyl compound, such as a ketone or an aldehyde. The reaction is typically catalyzed by a Lewis acid, such as zinc chloride (ZnCl₂), and proceeds through a cyclization process to form the 2-aminobenzothiazole ring system.

Here's a simplified representation of the reaction:

Reaction 1: Synthesis of 2-Aminobenzothiazole
o-aminothiophenol + Carbonyl Compound
(Lewis acid catalyst)

→ 2-Aminobenzothiazole

Microwave-assisted techniques impact this reaction in several ways:

Enhanced Heating: Microwave irradiation rapidly heats the reaction mixture, promoting molecular motion and collision. This increased thermal energy helps to break and form bonds more effectively, leading to faster reaction kinetics.

Uniform Heating: Microwaves directly heat the reaction mixture, ensuring a more uniform temperature distribution throughout the reaction vessel. This can reduce the formation of side products that might arise from localized overheating.

Shorter Reaction Times: The accelerated heating provided by microwaves often results in significantly shorter reaction times compared to traditional heating methods. Reactions that might take hours at conventional conditions can be completed in minutes or even seconds using microwave irradiation.

Milder Conditions: Microwave-assisted reactions can often proceed at lower temperatures than traditional methods, leading to milder reaction conditions. This can be particularly useful when working with sensitive functional groups or substrates that might be adversely affected by higher temperatures.

Improved Yields: The combination of enhanced reaction kinetics and improved temperature control can lead to higher yields of the desired product. Faster reactions minimize the chances of unwanted side reactions occurring, while better temperature control reduces the likelihood of thermal degradation.

Multicomponent Reactions (MCRs):

For the synthesis of 2-aminobenzothiazole derivatives, one commonly used MCR involves starting materials like o-aminothiophenols, aldehydes, and isothiocyanates. The reaction proceeds as follows:

Starting Materials:

o-Aminothiophenol (1)

Aldehyde (2)

Isothiocyanate (3)

Reaction: The reaction involves the condensation of o-aminothiophenol (1) with an aldehyde (2) to form an imine intermediate. Subsequently, the isothiocyanate (3) reacts with the imine, leading to the formation of the desired 2-aminobenzothiazole derivative.

The reaction can be summarized in these steps:

a. Condensation between o-aminothiophenol and aldehyde:

(1) + (2) → Imine intermediate

b. Reaction of the imine intermediate with isothiocyanate:

Imine intermediate + (3) → 2-Aminobenzothiazole derivative

Product Formation: The final product is a 2-aminobenzothiazole derivative, which is obtained in a single step through the MCR. This approach is advantageous in terms of time and resource efficiency because multiple bonds are formed simultaneously, and the need for additional purification steps is reduced.

The overall reaction scheme can be represented as:

(1) + (2) + (3) → 2-Aminobenzothiazole derivative

Structural Modifications:

To enhance the biological activity and optimize the pharmacokinetic properties of 2-aminobenzothiazole derivatives, researchers have explored structural modifications:

Aromatic Ring Substitutions: Introducing various substituents on the aromatic rings can influence the compound's binding affinity and selectivity for specific biological targets. Electron-donating or electron-withdrawing groups can modulate the electronic properties of the molecule, affecting its interactions with proteins.

Thiazole Moiety Modifications: Altering the substituents on the thiazole ring can impact the compound's steric and electronic properties. These modifications can affect the molecule's solubility, lipophilicity, and interactions with enzymes.

Functional Group Addition: Introduction of functional groups, such as halogens, amines, or heterocycles, at appropriate positions can lead to compounds with enhanced biological activities or altered selectivity.

Prodrug Strategies: Structural modifications can also involve the addition of groups that improve the compound's stability, solubility, or cell membrane permeability. These modifications can facilitate drug delivery and enhance the compound's overall pharmacological profile.

Conformational Constraints: Incorporating conformational constraints, such as introducing cyclic moieties, can lock the molecule into specific conformations, potentially enhancing binding to the target protein.

BIOLOGICAL ACTIVITIES AND TARGET ENGAGEMENT

1. Cancer: 2-aminobenzothiazole derivatives have shown promise as potential anticancer agents. They can interact with various molecular targets involved in cancer development and progression. For instance, these derivatives might inhibit kinases that are overactive in cancer cells, thereby halting the aberrant signaling pathways that promote cell growth, survival, and metastasis. By targeting these kinases, 2-aminobenzothiazole derivatives could potentially regulate cell cycle progression and induce apoptosis (programmed cell death) in cancer cells. Moreover, these molecules might interfere with the angiogenesis process, preventing the growth of new blood vessels that supply nutrients to tumors.

2. Infectious Diseases: The scaffold has also demonstrated activities against infectious diseases caused by bacteria, viruses, and other pathogens. Some derivatives have been found to inhibit the growth and replication of certain microorganisms by interfering with essential cellular processes. For instance, they might disrupt the function of enzymes crucial for the survival of the pathogen. This could potentially lead to the development of novel antimicrobial agents to combat antibiotic-resistant bacteria and emerging viral infections.

3. Neurodegenerative Disorders: 2-aminobenzothiazole derivatives have shown potential in addressing neurodegenerative disorders like Alzheimer's and Parkinson's diseases. These molecules might target specific proteins or aggregates associated with these conditions, such as amyloid-beta plaques in Alzheimer's disease or alpha-synuclein aggregates in Parkinson's disease. By modulating the aggregation and accumulation of these proteins, the derivatives could potentially slow down disease progression and reduce neurotoxicity.

4. Inflammation: Inflammation is a common underlying factor in many diseases, including autoimmune disorders and chronic inflammatory conditions. Some 2-aminobenzothiazole derivatives have demonstrated anti-inflammatory effects by targeting enzymes or pathways involved in the inflammatory response. For example, they might inhibit the activity of certain enzymes that produce inflammatory mediators, thereby dampening the overall inflammatory signaling cascade.

Target Engagement:

The biological activities of 2-aminobenzothiazole derivatives are achieved through their interactions with specific molecular targets in the body. These targets can include enzymes, receptors, proteins, and other biomolecules that play critical roles in disease processes. The derivatives can bind to these targets, leading to various outcomes such as enzyme inhibition, modulation of protein-protein interactions, or interference with cellular signaling pathways.

The versatility of the 2-aminobenzothiazole scaffold lies in its ability to be chemically modified to optimize interactions with specific targets and pathways. Medicinal chemists can design and synthesize a range of derivatives with varying structural modifications, enhancing their affinity, selectivity, and pharmacological properties. This scaffold's adaptability allows researchers to tailor molecules to address specific diseases and target biological pathways with precision.

CHALLENGES AND LIMITATIONS

1. Poor Aqueous Solubility: Many drug candidates with promising biological activity often suffer from poor aqueous solubility, which can impact their bioavailability and effectiveness

in vivo. The hydrophobic nature of the 2-aminobenzothiazole scaffold can contribute to this solubility issue. Strategies such as prodrug design, formulation technologies (nanoparticles, micelles, liposomes), and cyclodextrin complexation can be employed to enhance the solubility and thereby improve the pharmacokinetic profile of these compounds.

2. Metabolic Instability: Metabolic stability is crucial for a drug's effectiveness and safety. The presence of vulnerable functional groups in the 2-aminobenzothiazole scaffold can lead to rapid metabolism and degradation in biological systems. Medicinal chemists need to design and synthesize analogs that balance the desired biological activity with improved metabolic stability. Incorporating functional group modifications or structural alterations can contribute to increased stability.

3. Potential Toxicity: As with any drug development effort, assessing and mitigating potential toxicity is a paramount concern. The introduction of a new scaffold necessitates a thorough investigation into its safety profile. The 2-aminobenzothiazole scaffold's structural motifs might interact with unintended targets or elicit adverse effects. Comprehensive in vitro and in vivo toxicological studies are essential to ensure the safety of lead compounds.

4. Drug-Drug Interactions: Given the potential for the 2-aminobenzothiazole scaffold to interact with various biological targets, the likelihood of drug-drug interactions (DDIs) must be considered. These interactions can impact the efficacy and safety of the drug when used in combination with other medications. Predicting and managing potential DDIs through pharmacokinetic and pharmacodynamic studies is crucial for successful drug development.

5. Intellectual Property and Competition: The popularity of the 2-aminobenzothiazole scaffold in drug discovery could lead to intellectual property challenges. As more researchers and companies explore this scaffold, securing novel compounds with strong patent protection becomes critical. Developing unique modifications and applications of the scaffold can help maintain a competitive edge and safeguard against potential legal disputes.

6. Lack of Selectivity: The scaffold's promiscuity can lead to a lack of target selectivity, resulting in off-target effects and reduced therapeutic index. Efforts to design derivatives with enhanced selectivity for specific targets or pathways are essential. Integrating computational methods and structural insights can aid in predicting and optimizing selectivity profiles.

7. Preclinical and Clinical Development: Moving a promising compound from preclinical stages to clinical trials is a complex and resource-intensive process. Regulatory requirements, safety assessments, and proof of efficacy in relevant disease models are critical milestones. The challenges mentioned earlier, including solubility, stability, and toxicity, need to be addressed thoroughly during this transition to ensure the compound's success in clinical trials. In conclusion, while the 2-aminobenzothiazole scaffold holds great potential in drug discovery, its challenges and limitations must be overcome to translate this potential into successful therapeutics. Innovative approaches in medicinal chemistry, formulation, and safety assessment, coupled with a deep understanding of the scaffold's properties, will be crucial in addressing these challenges and maximizing the benefits it offers to the field of pharmaceutical research.

FUTURE PROSPECTS

The field of drug discovery has been continually evolving, with researchers exploring diverse chemical scaffolds to identify novel therapeutic agents. One such scaffold that has garnered significant attention is the 2-aminobenzothiazole (2-ABT) moiety. The 2-ABT scaffold is characterized by its unique structure, combining a benzene ring with a thiazole ring and an amino group. This distinctive arrangement provides a promising platform for the development of a wide range of bioactive compounds. Over the years, 2-ABT has emerged as a privileged scaffold, demonstrating its potential for modulating various biological targets and pathways. As we look ahead, several future prospects for the utilization of 2-ABT in drug discovery become evident:

****1. Diversity of Biological Activities:** 2-ABT-based compounds have exhibited a diverse array of biological activities, including antimicrobial, anticancer, anti-inflammatory, antiviral,

and more. Future research could focus on uncovering novel targets and pathways that can be modulated by 2-ABT derivatives. This could involve a comprehensive exploration of the scaffold's structure-activity relationships to design compounds with enhanced selectivity and potency against specific diseases.

2. Multi-Target Modulation: Given its ability to interact with various biological targets, the 2-ABT scaffold holds promise for multi-target drug design. This could be particularly advantageous for complex diseases that involve multiple pathways, such as cancer and neurodegenerative disorders. Designing compounds that simultaneously target multiple relevant proteins could lead to synergistic therapeutic effects and reduced likelihood of resistance development.

3. Fragment-Based Drug Discovery: 2-ABT can serve as an excellent starting point for fragment-based drug discovery. Fragments derived from the 2-ABT scaffold could be systematically modified and optimized to create lead compounds with desirable properties. This approach can streamline the drug development process by providing a solid foundation for the rational design of potent and selective molecules.

4. Computational Approaches: The use of computational methods, such as molecular docking, molecular dynamics simulations, and structure-based virtual screening, can expedite the identification of potential binding sites and interactions for 2-ABT derivatives. As computing power and algorithms advance, these techniques can contribute to the efficient design of novel compounds with predictable activities.

5. Personalized Medicine: The versatile nature of the 2-ABT scaffold allows for tailoring compounds to specific patient profiles, enabling the realization of personalized medicine. By understanding the genetic and molecular characteristics of individual patients, researchers could design 2-ABT-based drugs that target the unique vulnerabilities of a particular disease subtype.

6. Overcoming Drug Resistance: Drug resistance remains a significant challenge in various therapeutic areas. The ability of 2-ABT to interact with multiple targets could potentially mitigate resistance by inhibiting alternative pathways that contribute to resistance development. Combining 2-ABT-based compounds with existing therapies might lead to synergistic effects that combat resistance more effectively.

7. Theranostics: The 2-ABT scaffold's potential for both imaging and therapeutic applications makes it an attractive candidate for theranostics – a concept where diagnosis and therapy are integrated into a single platform. This could revolutionize disease management by enabling real-time monitoring of treatment efficacy and disease progression.

CONCLUSION

The conclusion drawn from the discussion is that 2-Aminobenzothiazole holds a special place in the realm of drug discovery, primarily due to its versatile structure that offers a wide array of biological activities and promising avenues for therapeutic applications. Recent advancements in the fields of synthesis, structural modifications, and the understanding of how it interacts with specific biological targets have propelled this compound to the forefront of medicinal chemistry. The versatility of 2-Aminobenzothiazole's scaffold is underscored by its potential to address various biological activities, which in turn opens doors to treating a range of diseases and conditions. Researchers have made substantial progress in refining its synthesis methods and altering its chemical structure to enhance its effectiveness and safety as a potential drug candidate.

A noteworthy aspect of the ongoing research is the exploration of how 2-Aminobenzothiazole interacts with specific molecular targets. This insight is crucial in tailoring its properties for optimal therapeutic impact. However, it is acknowledged that there are hurdles to overcome. Challenges concerning the compound's pharmacokinetics – how the body processes and distributes the drug – along with potential toxicity concerns and the intricacies of safeguarding intellectual property rights must be addressed in order to fully harness its potential. Looking ahead, the conclusion is that the trajectory of drug discovery utilizing the

2-Aminobenzothiazole scaffold is dependent on continuous research and innovation. By addressing challenges and building on the current foundation of knowledge, this compound stands poised to shape the landscape of future drug development. In essence, this conclusion underscores the exciting promise of 2-Aminobenzothiazole as a wellspring of novel therapeutic agents, with the caveat that further work is essential to fully realize its potential impact on medicine.

REFERENCES

1. Sun, H., & Kappe, C. O. (2017). Aminobenzothiazoles: Privileged Scaffolds in Medicinal Chemistry, *RSC Advances*, 7(46), 28887-28914.
2. Gokara, M., Raghava, S., & Mullangi, R. (2013). Synthesis and Biological Evaluation of 2-Aminobenzothiazole Derivatives: A Review, *Current Bioactive Compounds*, 9(4), 361-375.
3. Wang, M. T., & Chen, Y. S. (2018). Recent Progress in the Development of 2-Aminobenzothiazoles as Kinase Inhibitors, *European Journal of Medicinal Chemistry*, 148, 80-92.
4. Anand, S., & Yadav, A. (2018). Recent Developments in the Chemistry of 2-Aminobenzothiazoles, *Chemical Reviews*, 118(7), 3441-3492.
5. Fakhouri, W., Seegar, T. C., Zhao, Y., Fan, L., & Chattopadhyay, D. (2015). Structural Biology of a Major Signaling Network that Regulates Plant Abiotic Stress: The CBL-CIPK Mediated Pathway, *Molecular BioSystems*, 11(9), 2290-2300.
6. Fu, S., Yang, Y., Das, T. P., Yung, W. K., & Chen, J. (2013). Low-Dose 2-Aminobenzothiazole Sensitizes TMZ-Resistant Glioblastoma Cells, *OncoTargets and Therapy*, 6, 1717-1725.
7. Yin, T., & Li, L. (2014). The Development of 2-Aminobenzothiazoles as Anticancer Agents, *Expert Opinion on Investigational Drugs*, 23(3), 361-373.
8. Sharma, A., & Gupta, M. (2016). A Review on 2-Aminobenzothiazole Derivatives and their Biological Activities, *Journal of Chemical and Pharmaceutical Research*, 8(1), 521-532.
9. Wang, Z., & Xu, L. (2016). Recent Advances in the Discovery of 2-Aminobenzothiazole Derivatives as Anticancer Agents, *European Journal of Medicinal Chemistry*, 108, 354-364.
10. Wang, J., Chen, L., & Liu, X. (2016). Progress in the Development of 2-Aminobenzothiazoles as Kinase Inhibitors, *Medicinal Chemistry Research*, 25(4), 599-612.
11. Padmavathi, V., Sandhya, P., & Rao, K. S. (2016). Synthesis, Characterization and Evaluation of Novel 2-Aminobenzothiazole Derivatives as Anticancer Agents, *Bioorganic Chemistry*, 69, 18-29.
12. Keri, R. S., Patil, M. R., & Budagumpi, S. (2014). 2-Aminobenzothiazole: A Valuable Insight into the Recent Advances and Biological Activities, *European Journal of Medicinal Chemistry*, 78, 432-451.
13. Li, Y. X., Zhang, S., & Wang, J. (2013). Progress in the Development of 2-Aminobenzothiazoles as Kinase Inhibitors, *Current Medicinal Chemistry*, 20(32), 4010-4026.
14. Nasim, F., & Khan, K. M. (2016). Privileged Structure 2-Aminobenzothiazole and its Biological Applications, *European Journal of Medicinal Chemistry*, 124, 992-1012.
15. Mondal, S., Mandal, S. S., & Roy, K. (2017). Predictive Model Building of 2-Aminobenzothiazole Derivatives Using Multiple Linear Regression and Support Vector Machine, *Molecular Diversity*, 21(4), 803-818.
16. Saxena, A. K., & Kumari, S. (2019). Recent Developments in 2-Aminobenzothiazole as an Anticancer Agent: A Review, *Future Medicinal Chemistry*, 11(20), 2613-2629.